Liu Lucy Y, Teng Joyce M C, Spunt Sheri L, Strelo Jenna L, Kwong Bernice Y, Zaba Lisa C
Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA.
Department of Dermatology, Division of Pediatric Dermatology, Stanford University School of Medicine, Stanford, California, USA.
Pediatr Blood Cancer. 2021 Dec;68(12):e29346. doi: 10.1002/pbc.29346. Epub 2021 Sep 26.
Cutaneous adverse events (cAEs) from targeted antineoplastic agents and immune checkpoint inhibitors are common in children with cancer and may lead to dose reduction or cessation of critical oncologic treatment. Timely diagnosis and proper management of cAEs in pediatric oncology patients is essential to optimize ongoing cancer-directed therapy and improve quality of life. This systematic review of published studies summarizes dermatologic toxicities to targeted anticancer treatments and immune checkpoint inhibitors.
靶向抗肿瘤药物和免疫检查点抑制剂引起的皮肤不良事件（cAEs）在癌症患儿中很常见，可能导致关键肿瘤治疗的剂量减少或中断。及时诊断和妥善处理儿科肿瘤患者的cAEs对于优化正在进行的癌症导向治疗和提高生活质量至关重要。这项对已发表研究的系统评价总结了靶向抗癌治疗和免疫检查点抑制剂的皮肤毒性。
